Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups.
Bogani G, Apolone G, Ditto A, Scambia G, Panici PB, Angioli R, Pignata S, Greggi S, Scollo P, Delia M, Franchi M, Martinelli F, Signorelli M, Lopez S, Di Donato V, Valabrega G, Ferrandina G, Palaia I, Bergamini A, Bocciolone L, Savarese A, Ghezzi F, Casarin J, Pinelli C, Trojano V, Chiantera V, Giorda G, Sopracordevole F, Malzoni M, Salerno G, Sartori E, Testa A, Zannoni G, Zullo F, Vizza E, Trojano G, Chiantera A, Raspagliesi F. Bogani G, et al. Among authors: savarese a. J Gynecol Oncol. 2020 Nov;31(6):e92. doi: 10.3802/jgo.2020.31.e92. J Gynecol Oncol. 2020. PMID: 33078597 Free PMC article.
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Pignata S, et al. Among authors: savarese a. BMC Cancer. 2006 Aug 1;6:202. doi: 10.1186/1471-2407-6-202. BMC Cancer. 2006. PMID: 16882344 Free PMC article. Clinical Trial.
Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G. Ferrandina G, et al. Among authors: savarese a. Br J Cancer. 2008 Jun 17;98(12):1910-5. doi: 10.1038/sj.bjc.6604410. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506140 Free PMC article.
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Pignata S, et al. Among authors: savarese a. Oncology. 2009;76(1):49-54. doi: 10.1159/000178760. Epub 2008 Nov 27. Oncology. 2009. PMID: 19039248 Clinical Trial.
Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S. Magazzino F, et al. Among authors: savarese a. Int J Gynecol Cancer. 2011 Aug;21(6):1063-70. doi: 10.1097/IGC.0b013e318218f270. Int J Gynecol Cancer. 2011. PMID: 21633300
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Pignata S, et al. Among authors: savarese a. J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844495 Clinical Trial.
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K. Cognetti F, et al. Among authors: savarese a. Gynecol Oncol. 2013 Jul;130(1):31-7. doi: 10.1016/j.ygyno.2012.12.004. Epub 2012 Dec 9. Gynecol Oncol. 2013. PMID: 23234805 Clinical Trial.
128 results